Esmo 2021 – Astra finally sees a Wee1 signal
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Covid-19 stalls biotech flotations
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
